Overview CEQUA for Sjogren's Syndrome Dry Eye Status: Recruiting Trial end date: 2022-06-01 Target enrollment: Participant gender: Summary The primary objective of this study is to show that CEQUA (cyclosporine 0.09% ophthalmic solution) improves symptoms of dry eye disease in a population of patients with Sjogren's Syndrome diagnosis. Phase: Phase 4 Details Lead Sponsor: Center for Ophthalmic and Vision Research, LLCCollaborator: Sun Pharma Global FZETreatments: CyclosporineCyclosporinsOphthalmic Solutions